Navigation Links
Intercell AG Appoints Staph Leavenworth Bakali as Chief Business Officer

VIENNA, Sept. 30 /PRNewswire/ -- Intercell AG (VSE: ICLL) today announced that effective October 1, 2010, Staph Leavenworth Bakali will join its Management Board as Chief Business Officer with key responsibilities for the commercial aspects of the Company, directly leading Marketing and Sales, Corporate and Business Development, and Alliance Management. Staph will also play a key role with the other Management Board members in helping drive forward the Company's strategy. Prior to the appointment to Intercell AG's Management Board, Staph had stepped down from his position as member of the Supervisory Board of the company.

"Staph has an outstanding track record in the vaccines industry and has made major contributions to the success of some key vaccines businesses globally. His commercial and strategic experience ideally complement the skills of our current Management Board," said Gerd Zettlmeissl, Chief Executive Officer of Intercell AG. "We are proud to have Staph working with us towards the next growth phase of our Company."

"Having been a member of Intercell's Supervisory Board for almost five years, I have been impressed with the progress and capabilities of the Company and its people in creating value through innovation, industrialization and commercialization," said Staph Bakali. "I am delighted to join a very dynamic team and look forward to helping develop the business further."

Staph brings 20 years of vaccine industry experience from his previous leadership positions. He was recently Chief Executive Officer of Genocea Biosciences, a Boston (U.S.) based innovative biotech vaccine company, and previously Chief Operating Officer for ID Biomedical (Vancouver, Canada) and PowderJect (Oxford, UK), which were acquired by GlaxoSmithKline and Chiron, respectively. Staph Bakali was also previously head of Sales and Marketing for Chiron's global vaccine business and SmithKline Beecham's Vaccine Business Unit in France. Staph holds a Masters degree in Management from the London Business School.

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

SOURCE Intercell AG
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases
2. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
3. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
4. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
5. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
6. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
7. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
8. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
9. 3-V Biosciences Appoints Merdad V. Parsey, MD, PhD, as Chief Executive Officer
10. Tigris Pharmaceuticals Appoints Neil Flanzraich to Executive Chairman of the Board
11. Laureate Pharma Appoints Steven R. Johnson as Vice President, Business Development
Post Your Comments:
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Frederick area economy by obtaining investment capital for emerging technology companies. ... years that have already resulted in more than a million dollars of capital ...
Breaking Medicine News(10 mins):